Larimar Therapeutics Inc. (LRMR)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 0 |
| Ownership rank: | -- |
| % of all portfolios: | 0% |
| |
| Total insider Buys/Sells last 6 months: |
| Transactions | Total |
| Buys |
0 |
$0 |
| Sells |
0 |
$0 |
|
Portfolio Manager |
% of portfolio |
Recent activity |
Shares |
Value |
Open Market Insider Buys
| Date Filed |
Reporting Name |
Relationship |
Trans. Date |
Shares |
Price $ |
Total Value $ |
| 31 May 2024 |
HAMILTON THOMAS EDWARD |
Director |
16 Feb 2024 |
57,208 |
8.74 |
499,998 |
| 16 Feb 2024 |
FLYNN JAMES E |
Director , 10% |
16 Feb 2024 |
1,430,206 |
8.74 |
12,500,000 |
| 16 Feb 2024 |
FLYNN JAMES E |
Director , 10% |
16 Feb 2024 |
1,430,205 |
8.74 |
12,499,992 |
| 15 Feb 2024 |
THOMAS FRANK E |
Director |
14 Feb 2024 |
2,000 |
11.00 |
22,000 |
| 08 Dec 2023 |
SHANKAR GOPI |
Chief Development Officer |
07 Dec 2023 |
5,000 |
3.73 |
18,662 |
| 18 May 2023 |
CELANO MICHAEL |
Chief Financial Officer |
17 May 2023 |
5,000 |
3.73 |
18,632 |
| 18 May 2023 |
BEN-MAIMON CAROLE |
President and CEO |
17 May 2023 |
5,000 |
3.70 |
18,525 |
| 18 May 2023 |
TRUITT JOSEPH |
Director |
17 May 2023 |
2,750 |
3.73 |
10,258 |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.
P = Preferred Stock